Table 1.
Clinical and Molecular Characteristics of Patients with Adenocarcinoma of the Esophagus
| Case | Sex | Age (yrs) | Size (cm) | Stage/Lauren’s* | p53 IHC (% cells) | TP53 mutation† | mdm2 IHC (% cells)‡ | MDM2 amplification§ |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 69 | 7.5 | T1N0/INT | <10 | 135 | >50 | − |
| 2 | M | 62 | 1 | T1N0/INT | na | 220 | Na | − |
| 3 | M | 69 | 5 | T1N0/INT | 0 | − | >50 | − |
| 4 | M | 80 | 7 | T1N0/INT | 0 | − | 20 | − |
| 5 | M | 50 | 2 | T2N0/INT | >50 | 230 | 0 | − |
| 6 | M | 82 | 5 | T2N0/INT | 0 | − | 0 | − |
| 7 | M | 70 | 4 | T2N0/INT | 0 | − | 10−20 | − |
| 8 | M | 67 | 8 | T3N0/DIF | 0 | − | 0 | − |
| 9 | M | 53 | 4 | T3N0/INT | >50 | 282 | 0 | − |
| 10 | M | 71 | 2.5 | T3N0/INT | na | − | 20−50 | − |
| 11 | M | 82 | 2 | T3N0/INT | 0 | − | 0 | − |
| 12 | M | 72 | 3.5 | T3N0/INT | >50 | 272 | 0− | |
| 283 | ||||||||
| 13 | M | 74 | 4 | T3N0/INT | <10 | − | 0 | − |
| 14 | M | 49 | 4.5 | T3N0/INT | 0 | − | >50 | − |
| 15 | M | 69 | 5 | T3N1/INT | >50 | 157 | Na | − |
| 16 | M | 68 | 3.5 | T3N1/INT | 20–50 | 159 | 0 | − |
| 17‡ | M | 76 | 3 | T3N1/INT | 0 | 175 | 0 | − |
| 18 | M | 72 | 3.5 | T3N1/INT | 0 | 234 | 0 | − |
| 19 | F | 73 | 6 | T3N1/INT | 0 | 279 | >50 | − |
| 20 | M | 66 | 9 | T3N1/INT | 0 | − | 0 | − |
| 21 | M | 76 | 2.5 | T3N1/INT | 0 | − | 0 | − |
| 22 | M | 60 | 4 | T3N1/INT | 0 | − | 0 | − |
| 23 | M | 65 | n.d∥ | n.d/INT | 20–50 | 213 | Na | − |
| 24 | M | 61 | n.d | n.d/INT | >50 | 245 | 20−50 | − |
| 25 | M | 73 | n.d | n.d/INT | 0 | 38 | >50 | − |
| 26 | M | 70 | n.d | n.d/INT | >50 | 237 | Na | − |
| 27 | M | 70 | n.d | n.d/INT | 10–20 | − | <10 | − |
| 28 | M | 65 | n.d | n.d/INT | 0 | − | >50 | + |
| 29¶ | M | 58 | 12 | T1N0/INT | 0 | − | 20 | + |
| 30 | F | 25 | 2.5 | T2N0/INT | 0 | 213 | 0 | − |
| 31 | F | 59 | 5.5 | T3N0/DIF | 0 | − | >50 | − |
| 32 | M | 45 | 7 | T3N0/INT | 0 | 163 | 0 | − |
| 33¶ | F | 70 | 1.2 | T3N0/INT | >50 | 220 | 0 | − |
| 34 | F | 72 | 9.5 | T3N0/INT | 0 | − | 0 | − |
| 35 | M | 41 | 2 | T3N1/DIF | 0 | − | 0 | − |
| 36 | M | 56 | 7 | T3N1/DIF | 0 | − | 0 | − |
| 37 | M | 50 | 8 | T3N1/DIF | 0 | − | >50 | − |
| 38¶ | M | 82 | 10 | T3N1/INT | 0 | 175 | 0 | − |
| 39 | M | 77 | 6 | T3N1/INT | 0 | 213 | Atypical | − |
| 40 | M | 70 | 5 | T3N1/INT | >50 | 220 | 0 | − |
| 41 | M | 61 | 2.5 | T3N1/INT | 10–20 | 273 | 0 | − |
| 42¶ | F | 69 | 7 | T3N1/INT | 20–50 | 282 | >50 | − |
| 43 | M | 63 | 7 | T3N1/INT | 0 | − | 0 | − |
| 44 | M | 64 | 2.5 | T3N1/INT | 0 | − | 0 | − |
| 45 | F | 60 | 4 | T3N1/INT | 10–20 | − | >50 | + |
| 46¶ | F | 56 | 6 | T3N1/INT | 0 | − | >50 | + |
| 47 | F | 80 | 2.5 | T3N1/INT | 0 | − | 20–50 | − |
| 48 | M | 62 | 4.5 | T3N1/INT | 0 | − | 0 | − |
| 49 | M | 70 | 5.5 | T3N1/INT | 0 | − | 0 | − |
| 50 | M | 58 | 6 | T3N1/INT | 0 | − | >50 | − |
| 51 | M | 70 | 4 | T3N1/INT | 0 | − | >50 | + |
| 52 | M | 79 | 7 | T3N1/INT | 0 | − | 10–20 | − |
| 53 | F | 74 | 2.5 | T3N1/INT | 0 | − | >50 | + |
| 54 | M | 63 | 7 | T3N1/INT | 0 | − | >50 | − |
*Lauren’s classification: Int, intestinal type; Dif, diffuse type.
†Mutations were identified by temporal temperature gradient electrophoresis/sequencing, except for cases 12 and 33 (yeast functional assay/sequencing).
‡IHC, immunohistochemistry.
§+, amplification of MDM2, as detected by a MDM2/DRD2 signal ratio ≥2.5.
¶Additional tumors: squamous cell carcinoma of head and neck (n = 17); pleomorphic adenoma of the parotid (n = 29); adenocarcinoma of the breast (n = 33); adenocarcinoma of the intestine (n = 38); adenocarcinoma of the breast (n = 42); malignant melanoma and adenocarcinoma of the breast (n = 46).
∥n.d; not determined.